Latest Information Update: 27 Jan 2016
At a glance
- Originator Aspen Park Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypogonadism
Most Recent Events
- 27 Jan 2016 Preclinical trials in Hypogonadism in USA (PO) before January 2016
- 27 Jan 2016 Aspen Park Pharmaceuticals plans a phase II trial for Hypogonadism (Aspen Park Pharmaceuticals pipeline)